Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

Oncologist

Volumn 12, Issue 9, 2007, Pages 1035-1043

  Lipton, Allan ^a   Cook, Richard J ^b   Major, Pierre ^a,c   Smith, Matthew R ^d   Coleman, Robert E ^e  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Biologic markers; Breast neoplasms; Survival rate; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CELL MARKER; CREATININE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CELL ACTIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE FREE SURVIVAL; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; OSTEOCLAST; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; URINE LEVEL;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; CREATININE; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; PEPTIDES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35548960086     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-9-1035     Document Type: Article

References (27)

1. Manders K, van de Poll-Franse LV, Creemers GJ et al. Clinical management of women with metastatic breast cancer: A descriptive study according to age group. BMC Cancer 2006;6:179.
2. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
3. Weinfurt KP, Castel LD, Li Y et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-175.
4. Lipton A, Costa L, Ali SM et al. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001;27:181-185.
5. Costa L, Demers LM, Gouveia-Oliveira A et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
6. Vinholes JJ, Purohit OP, Abbey ME et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-1250.
7. Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
8. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
9. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
10. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474.
11. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
12. Rosen CJ, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-1910.
13. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
14. Hosmer DW, Lemeshow S. Applied Logistic Regression, Second Edition. Hoboken, NJ: Wiley InterScience, 2000:1-392.
15. Lawless JF. Statistical Models and Methods for Lifetime Data, Second Edition. Hoboken, NJ: Wiley InterScience, 2003:1-664.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, Second Edition. Hoboken, NJ: Wiley InterScience, 2002:1-462.
17. Grambsch PM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
18. Demers LM, Costa L, Chinchilli VM et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-1494.
19. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
20. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
21. Green JR. Bisphosphonates: Preclinical review. The Oncologist 2004;9(suppl 4):3-13.
22. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;31(suppl 3):1-8.
23. Hiraga T, Williams PJ, Ueda A et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-4567.
24. Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492.
25. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201.
26. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13.
27. Hei Y, Saad F, Coleman RE et al. Fractures negatively affect survival in patients with bone metastases from breast cancer. Breast Cancer Res Treat 2005;94(suppl 1):S260.